OR WAIT null SECS
The expansion will enable relocation of its North American headquarters from Grayslake, Illinois.
Xellia Pharmaceuticals announced that it has expanded its Raleigh site. The expansion will enable relocation of its North American headquarters from Grayslake, Illinois.
One year following its acquisition of the Raleigh plant from Fresenius Kabi, Xellia has added new premises adjacent to its dedicated lyophilized vial manufacturing facility. The expansion consolidates company’s commercial function and manufacturing facility in one location, forming the new headquarters. Employees at the Grayslake site have begun a phased relocation.
Xellia has more than 100 years of pharmaceutical industry experience and specializes in difficult-to-manufacture and develop anti-infective products. The company is increasingly moving on from its origins as a manufacturer of APIs to better serve its global customer base of over 500 pharmaceutical companies by supplying the finished dosage forms of its drugs.
Source: Xellia Pharmaceuticals